Research News and Research

RSS

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

CHUM neurosurgeon raises funds for epilepsy research

On January 8, 2010, CHUM neurosurgeon Dr. Alain Bouthillier will leave for Argentina, where he will brave the 6,962-metre heights (over 22,840 feet) of Mount Aconcagua. Dr. Bouthillier's climb is intended to raise public awareness about epilepsy and raise funds for further research on the illness.

15 Dec 2009

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, according to a study in the December 16 issue of JAMA.

15 Dec 2009

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

Springer and BSRA sign three-year agreement

Springer has just signed an agreement with the British Society for Research on Ageing (BSRA) to enter into an affiliation with the journal Biogerontology for an initial period of three years.

15 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

U.S. questions California's CHIP program; Milwaukee schools face rising retiree health care costs

News outlets report on California's children's health program, health care costs for Milwaukee's schools and indigent care in Minnesota.

15 Dec 2009

Data shows drop in natural disaster-related deaths, growing economic losses; Sen. Murkowski moves to halt EPA greenhouse gas regulation

New data from the WHO and the Belgian Centre for Research on Epidemiology of Disasters Deaths and released at the U.N. climate conference show the number of people dying in climate-related disasters has decreased, and that economic losses from natural disasters are growing, Reuters AlertNet reports.

15 Dec 2009

Also in Global Health news: Drug trafficking in Kenya; violence in S. Sudan; Uganda bill; sleeping sickness

Drug trafficking and use are fueling the spread of HIV/AIDS in Kenya, according to a recent report by the U.N. Security Council, the Nation reports. "A statement from the council's Presidency currently … states that Afghan heroin was being imported, causing a dramatic increase in heroin addiction and spreading HIV/AIDS in the slums of Nairobi and Mombasa, Kenya's two main cities," the newspaper writes.

15 Dec 2009

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Genocea Biosciences, a leading vaccine discovery and development company, today announced it has been awarded a grant from the University of Pittsburgh Medical Center’s (UPMC) Sexually Transmitted Infections (STI) Cooperative Research Center for the development of vaccines for Chlamydia trachomatis.

15 Dec 2009

Almac Discovery initiates Phase I clinical trial of intranasal Granisetron for CINV

Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).

15 Dec 2009

Prescription drug import amendment divides Senate Democrats

The Senate is battling over a proposed amendment that would allow prescription drugs to be imported from other countries where prices are lower.

15 Dec 2009

Tibotec Virco Virology BVBA acquires Ground Zero Software's LAB TRACKER HIV EMR system

Tibotec Virco Virology BVBA today announced the acquisition of LAB TRACKER(TM) HIV, a customized electronic medical record (EMR) system, from the company Ground Zero Software. LAB TRACKER(TM) HIV is a full-service, scalable software platform designed to meet the complex disease-management needs of health care providers who are treating people living with HIV/AIDS.

15 Dec 2009

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Interpersonal Psychotherapy may hold hope for teenager girls at risk of obesity

A team of scientists at the Uniformed Services University of the Health Sciences and the National Institutes of Health have piloted psychotherapy treatment to prevent excessive weight gain in teenager girls deemed 'at risk' for obesity.

15 Dec 2009

Cellular and subcellular effects of PACE technology presented

SANUWAVE Health, Inc., (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that the cellular and subcellular effects of PACE™ technology were described during a lecture presented this past weekend.

15 Dec 2009

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

15 Dec 2009

Research News and Research

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

CHUM neurosurgeon raises funds for epilepsy research

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

Springer and BSRA sign three-year agreement

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Positive results from study comparing exenatide once weekly to BYETTA

U.S. questions California's CHIP program; Milwaukee schools face rising retiree health care costs

Data shows drop in natural disaster-related deaths, growing economic losses; Sen. Murkowski moves to halt EPA greenhouse gas regulation

Also in Global Health news: Drug trafficking in Kenya; violence in S. Sudan; Uganda bill; sleeping sickness

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Almac Discovery initiates Phase I clinical trial of intranasal Granisetron for CINV

Prescription drug import amendment divides Senate Democrats

Tibotec Virco Virology BVBA acquires Ground Zero Software's LAB TRACKER HIV EMR system

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Interpersonal Psychotherapy may hold hope for teenager girls at risk of obesity

Cellular and subcellular effects of PACE technology presented

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News